ATE150645T1 - Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen - Google Patents
Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungenInfo
- Publication number
- ATE150645T1 ATE150645T1 AT92118219T AT92118219T ATE150645T1 AT E150645 T1 ATE150645 T1 AT E150645T1 AT 92118219 T AT92118219 T AT 92118219T AT 92118219 T AT92118219 T AT 92118219T AT E150645 T1 ATE150645 T1 AT E150645T1
- Authority
- AT
- Austria
- Prior art keywords
- bmy
- withdrawal symptoms
- patients experiencing
- treat anxiety
- benzodiazepine withdrawal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78201091A | 1991-10-24 | 1991-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE150645T1 true ATE150645T1 (de) | 1997-04-15 |
Family
ID=25124656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92118219T ATE150645T1 (de) | 1991-10-24 | 1992-10-23 | Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5278164A (de) |
| EP (1) | EP0538897B1 (de) |
| JP (1) | JPH05238934A (de) |
| KR (1) | KR100196334B1 (de) |
| AT (1) | ATE150645T1 (de) |
| AU (1) | AU649169B2 (de) |
| CA (1) | CA2081062A1 (de) |
| CY (1) | CY2019A (de) |
| DE (1) | DE69218544T2 (de) |
| DK (1) | DK0538897T3 (de) |
| ES (1) | ES2101000T3 (de) |
| GR (1) | GR3022945T3 (de) |
| HK (1) | HK113897A (de) |
| IL (1) | IL103499A0 (de) |
| OA (1) | OA09766A (de) |
| PH (1) | PH30028A (de) |
| TW (1) | TW217382B (de) |
| ZA (1) | ZA928105B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011091418A1 (en) * | 2010-01-25 | 2011-07-28 | Northeastern University | Screening method for adverse side effects of a therapeutic pharmaceutical drug |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605655A (en) * | 1984-03-06 | 1986-08-12 | Bristol-Myers Company | Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives |
| US5055470A (en) * | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
-
1992
- 1992-10-21 AU AU27165/92A patent/AU649169B2/en not_active Ceased
- 1992-10-21 IL IL103499A patent/IL103499A0/xx unknown
- 1992-10-21 CA CA002081062A patent/CA2081062A1/en not_active Abandoned
- 1992-10-21 TW TW081108399A patent/TW217382B/zh active
- 1992-10-22 OA OA60291A patent/OA09766A/en unknown
- 1992-10-22 ZA ZA928105A patent/ZA928105B/xx unknown
- 1992-10-22 PH PH45145A patent/PH30028A/en unknown
- 1992-10-22 JP JP4324571A patent/JPH05238934A/ja not_active Ceased
- 1992-10-23 DE DE69218544T patent/DE69218544T2/de not_active Expired - Fee Related
- 1992-10-23 AT AT92118219T patent/ATE150645T1/de not_active IP Right Cessation
- 1992-10-23 ES ES92118219T patent/ES2101000T3/es not_active Expired - Lifetime
- 1992-10-23 EP EP92118219A patent/EP0538897B1/de not_active Expired - Lifetime
- 1992-10-23 KR KR1019920019562A patent/KR100196334B1/ko not_active IP Right Cessation
- 1992-10-23 DK DK92118219.2T patent/DK0538897T3/da active
-
1993
- 1993-06-01 US US08/069,654 patent/US5278164A/en not_active Expired - Lifetime
-
1997
- 1997-03-27 GR GR970400379T patent/GR3022945T3/el unknown
- 1997-06-26 HK HK113897A patent/HK113897A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY201998A patent/CY2019A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0538897T3 (da) | 1997-08-25 |
| ES2101000T3 (es) | 1997-07-01 |
| TW217382B (de) | 1993-12-11 |
| HK113897A (en) | 1997-08-29 |
| AU2716592A (en) | 1993-04-29 |
| CY2019A (en) | 1998-02-20 |
| IL103499A0 (en) | 1993-03-15 |
| CA2081062A1 (en) | 1993-04-25 |
| EP0538897B1 (de) | 1997-03-26 |
| US5278164A (en) | 1994-01-11 |
| KR930007452A (ko) | 1993-05-20 |
| PH30028A (en) | 1996-11-08 |
| ZA928105B (en) | 1993-08-25 |
| OA09766A (en) | 1993-11-30 |
| EP0538897A1 (de) | 1993-04-28 |
| DE69218544D1 (de) | 1997-04-30 |
| KR100196334B1 (ko) | 1999-06-15 |
| JPH05238934A (ja) | 1993-09-17 |
| GR3022945T3 (en) | 1997-06-30 |
| DE69218544T2 (de) | 1997-11-13 |
| AU649169B2 (en) | 1994-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69203596T2 (de) | Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven. | |
| SE8703625D0 (sv) | New medical use | |
| DE69403969D1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| DE69230046T2 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| DE69526937T2 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE69121561D1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| DE69431199T2 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen | |
| DE69301750T2 (de) | Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose | |
| ATE150645T1 (de) | Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen | |
| SE9101341D0 (sv) | New medicinal use | |
| DE69113773D1 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
| DE3585312D1 (de) | Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden. | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis | |
| DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen | |
| UA12890A (uk) | Спосіб акупуhктури |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |